BEONE MEDICINES LTD. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
BEONE MEDICINES LTD. (BEIGF) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $448.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- BEONE MEDICINES LTD. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $448.70M, a 541.49% increase from fiscal 2024.
- BEONE MEDICINES LTD. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $69.95M, a 24.01% decline from fiscal 2023.
- BEONE MEDICINES LTD. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $92.05M, a 76.15% increase from fiscal 2022.
- BEONE MEDICINES LTD. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $52.26M, a 85.77% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $448.70M 10-K · filed 2026-02-26 |
| 2024-12-31 | $69.95M 10-K · filed 2025-02-27 |
| 2023-12-31 | $92.05M 10-K · filed 2025-02-27 |
| 2022-12-31 | $52.26M 10-K · filed 2025-02-27 |
| 2021-12-31 | $367.11M 10-K · filed 2024-02-26 |
| 2020-12-31 | $416.51M 10-K · filed 2023-02-27 |
| 2019-12-31 | $171.43M 10-K · filed 2022-02-28 |